Compare GL & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GL | ABVX |
|---|---|---|
| Founded | 1900 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Life Insurance | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3B | 11.9B |
| IPO Year | 1998 | 2022 |
| Metric | GL | ABVX |
|---|---|---|
| Price | $179.41 | $120.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $167.27 | $131.31 |
| AVG Volume (30 Days) | 640.7K | ★ 829.0K |
| Earning Date | 04-22-2026 | 03-23-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | ★ 17.84 | N/A |
| EPS | ★ 7.04 | N/A |
| Revenue | ★ $5,994,318,000.00 | N/A |
| Revenue This Year | $9.64 | $52.14 |
| Revenue Next Year | $5.61 | $4,132.27 |
| P/E Ratio | $25.71 | ★ N/A |
| Revenue Growth | ★ 3.74 | N/A |
| 52 Week Low | $127.85 | $67.15 |
| 52 Week High | $191.55 | $148.83 |
| Indicator | GL | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 50.46 | 46.14 |
| Support Level | $174.84 | $107.67 |
| Resistance Level | $182.32 | $130.87 |
| Average True Range (ATR) | 3.58 | 4.74 |
| MACD | -0.72 | -1.08 |
| Stochastic Oscillator | 23.85 | 28.87 |
Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.